Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Corey E. Clin Cancer Res 7: 2977-83, 2001. PMID: 11595685
A single dose of sustained-duration PTH-(1-34)-Fc increases serum markers of bone formation for 28 days in cynomogus monkeys. Stouch BJ, Kostenuik P, Gunn H, Baughman S, DePaoli A, Dunstan CR, and Martin SW. J Bone Miner Res 18 (Suppl. 2): S165, 2003 (Abstract)
RANKL and TRAP-5b are markers of bone destruction in two rat models of inflammatory arthritis. Kostenuik PJ, Stolina M, Bolon B, Adamu S, Asuncion F, Morony S, Schett G, Middleton S, Feige U, Zack D. J Bone Miner Res 19 (Suppl. 1): S189, 2004 (Abstract)
Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins. Abrahamsen B, Hjelmborg JVB, Kostenuik PJ, et al. Bone 36: 727-735, 2005. PMID: 15781001
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. Stolina S, Adamu S, Schett G, et al. J Bone Miner Res 20: 1756-1765, 2005. PMID: 16160733
Biochemical markers of bone turnover predict BMD changes at cortical and cancellous sites in a 16-month study of denosumab (a fully human monoclonal RANKL antibody) in aged ovariectomized cynomolgus monkeys. Ominsky MS, Smith SY, Farrell DJ, Schroeder J, Atkinson JE, Kostenuik PJ. Osteoporosis Int 80 (Suppl. 1): S140, 2007 (Abstract)
The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Stolina M, Bolon B, Middleton S, et al. Biomarkers 13: 692-712, 2008. PMID: 19096963
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. Stolina M, Bolon B, Middleton S, Dwyer D, et al. J Clin Immunol 29: 158-174, 2009. PMID: 18726678
Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Li XL, Ominsky MS, Stolina M, et al. Bone 45: 669-676, 2009. PMID: 19539794
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. Drake MT, Srinivasan B, Modder UI, et al. J Clin Endocrinol Metab 95: 5056-5062, 2010. PMID: 20631014
Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density and strength in ovariectomized cynomolgus monkeys. Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ. Bone 49: 151-161, 2011. PMID: 21497676
OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. Sipos W, Zysset P, Kostenuik P, et al. Horm Metab Res 43: 944-9, 2011. PMID: 22161252
Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Shahnazari M, Dwyer D, Chu V, et al. Bone 50: 628-637, 2012. PMID: 22154841
Integrin AvB3 as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Zheleznyak A, Wadas TJ, Sherman CD, et al. Mol Biol Imaging 14: 500-508, 2012. PMID: 21853370
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Stolina M, Dwyer D, Villasenor KS, et al. Bone 67: 305-313, 2014. PMID: 25093263
Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. Kostenuik PJ, Smith SY, Samadfam R, et al. J Bone Miner Res 30: 657-669, 2015. PMID: 25369992
Some of Dr. Kostenuik's publications in the biomarker field:
Dr. Kostenuik directed a clinical and preclinical biomarker laboratory for
12 years. His group used cutting-edge techniques for high-throughput analysis of hundreds of biomarkers from blood, urine, tissues, organs and cells, including proteins, clinical chemistry analytes, DNA and RNA. This work often involved novel assay development and validation to serve the needs of a wide variety of therapeutic areas.
Biomarkers